In the treatment of deep vein thrombosis, the EINSTEIN-PE and EINSTEIN-DVT trials demonstrated non-inferiority of which agent compared to conventional heparin–warfarin therapy?

• A Apixaban
• B Dabigatran
• C Edoxaban
• D Rivaroxaban ✓

Explanation

The EINSTEIN-DVT and EINSTEIN-PE trials specifically evaluated rivaroxaban (Factor Xa inhibitor) against enoxaparin–vitamin K antagonist for VTE treatment. Rivaroxaban was non-inferior for efficacy (recurrent VTE) with a significantly lower rate of major bleeding in PE. These trials established rivaroxaban as a single-drug oral regimen, obviating the need for initial parenteral anticoagulation.

Reference: Bailey & Love's Short Practice of Surgery, 27th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.